A Guth Labs publication ↗
Back to News

Fangzhou and Baiyunshan partner on AI-supported chronic care

Flowing green glass loop joined by a gold connector to an unmarked cream capsule.
AI-generated editorial illustration

Fangzhou announced a partnership with Baiyunshan Pharmaceutical General Factory on November 19 to expand AI-supported chronic disease services and develop digital marketing capabilities in China.

The company announcement says the agreement was presented at Fangzhou’s partner conference in Guangzhou. It builds on more than a decade of collaboration between the companies.

Fangzhou says it has expanded AI use in health monitoring, patient follow-up and health education, while upgrading its AI Health Manager, Medication Assistant and pre-consultation tools. Planned integrated services include online health assessments, individual follow-up, professional guidance and prescription fulfillment.

The partners intend to combine Fangzhou’s healthcare platform with Baiyunshan’s pharmaceutical portfolio and industry experience. The release does not disclose financial terms, a deployment timetable or independently measured clinical outcomes.

That distinction matters: this is an announced service and marketing partnership, not evidence that AI has improved treatment results. Its significance is the proposed connection between digital follow-up and pharmaceutical services across ongoing chronic care, rather than a new medicine or autonomous medical decision-making system.

Sources and citations

Revision history

Published .